Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178644 · ClinicalTrials.gov registry record · Phase 1
Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02178644 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 29 participants.
The verdict
NCT02178644, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This pilot study focuses on KD018 and will investigate the effect of this agent on reducing the Gastrointestinal (GI) toxicity associated with combined modality therapy of locally-advanced rectal cancer.
Interventions
- DRUG Chemo with concomitant Capecitabine and KD018
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02178644
The ClinicalTrials.gov registry entry for NCT02178644 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chemo with concomitant Capecitabine and KD018 is the first listed.
NCT02178644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02178644 about?
NCT02178644 is a clinical study titled "Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer". This pilot study focuses on KD018 and will investigate the effect of this agent on reducing the Gastrointestinal (GI) toxicity associated with combined modality therapy of locally-advanced rectal cancer.
What is the current status of trial NCT02178644?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-07. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT02178644?
The interventions under investigation include: Chemo with concomitant Capecitabine and KD018 (DRUG).
Who is sponsoring clinical trial NCT02178644?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.